112
Participants
Start Date
August 30, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
March 31, 2028
Nivolumab 40 mg in 4 ml Injection
Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
Ipilimumab 200 MG in 40 ML Injection
Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
Chemoradiation
Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
RECRUITING
CRIO -Centro Regional Integrado de Oncologia, Fortaleza
RECRUITING
Clinica AMO, Salvador
NOT_YET_RECRUITING
Hospital das Clinicas da UFMG, Belo Horizonte
NOT_YET_RECRUITING
Hospital Erasto Gaertner, Curitiba
RECRUITING
Multi Oncoclinicas Recife, Recife
NOT_YET_RECRUITING
Hospital São Lucas - PUCRS, Porto Alegre
RECRUITING
Universidade Federal de Roraima, Boa Vista
NOT_YET_RECRUITING
CEPON - Florianópolis, Florianópolis
NOT_YET_RECRUITING
Hospital de Amor, Barretos
NOT_YET_RECRUITING
Hospital De Base de São José do Rio Preto - CIP São José, São José do Rio Preto
NOT_YET_RECRUITING
INCA - Instituto Nacional do Cancer, Rio de Janeiro
NOT_YET_RECRUITING
AC Camargo Cancer Center, São Paulo
RECRUITING
Hospital Municipal Vila Santa Catarina, São Paulo
RECRUITING
Hospital Israelita Albert Einstein, São Paulo
Collaborators (2)
Bristol-Myers Squibb
INDUSTRY
Brava
INDUSTRY
Hospital Israelita Albert Einstein
OTHER